Fortis Inc. Provides Standby Commitment to Caribbean Utilities Company, Ltd.
September 23, 2024 06:00 ET
|
Fortis
ST. JOHN'S, Newfoundland and Labrador, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE: FTS) announced today that its wholly owned subsidiary...
Brunswick Corporation’s award-winning 2024 Cannes Yachting Festival includes new product announcements and leading market share
September 23, 2024 06:00 ET
|
Brunswick Corporation
CANNES, France, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Brunswick Corporation, (NYSE: BC), and many of its industry leading brands, wrapped up another successful Cannes Yachting Festival with leading...
Caledonia Mining Corporation Plc: Fatal accident at Blanket Mine
September 23, 2024 02:00 ET
|
Caledonia Mining Corporation Plc
Caledonia Mining Corporation Plc reports an accident in Zimbabwe.
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024 01:00 ET
|
Teva Pharmaceutical Industries Ltd
RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an...
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024 04:15 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
Brookfield Corporation Announces Results of Conversion of its Series 40 Preferred Shares
September 20, 2024 16:45 ET
|
Brookfield Corporation
BROOKFIELD, NEWS, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Brookfield Corporation (NYSE: BN, TSX: BN) today announced that after having taken into account all election notices received by the deadline for...
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
September 20, 2024 16:05 ET
|
iBio, Inc.
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
Minerals Technologies Announces Participation in Gabelli Funds 2nd Annual PFAS Symposium
September 20, 2024 13:00 ET
|
Minerals Technologies Inc.
NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) announced participation in Gabelli Funds PFAS Symposium in New York City on Thursday, September 26, 2024. Minerals...
Transaction in Own Shares
September 20, 2024 12:36 ET
|
Shell plc
Transaction in Own Shares 20 September, 2024 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 20 September 2024 it purchased the following number of Shares for...